Literature DB >> 8235612

Determination of type I receptor specificity by the type II receptors for TGF-beta or activin.

R Ebner1, R H Chen, S Lawler, T Zioncheck, R Derynck.   

Abstract

Transforming growth factor-beta (TGF-beta) and activin signal primarily through interaction with type I and type II receptors, which are transmembrane serine-threonine kinases. Tsk 7L is a type I receptor for TGF-beta and requires coexpression of the type II TGF-beta receptor for ligand binding. Tsk 7L also specifically bound activin, when coexpressed with the type IIA activin receptor. Tsk 7L could associate with either type II receptor and the ligand binding specificity of Tsk 7L was conferred by the type II receptor. Tsk 7L can therefore act as type I receptor for both activin and TGF-beta, and possibly other ligands.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8235612     DOI： 10.1126/science.8235612

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  44 in total

1.  Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.

Authors:  Q Wang; Y Wang; D M Hyde; P J Gotwals; V E Koteliansky; S T Ryan; S N Giri
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  TGF-beta in mammary development and neoplasia.

Authors:  C L Arteaga; H L Moses
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-10       Impact factor: 2.673

3.  Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling.

Authors:  Geeta Upadhyay; Yuzhi Yin; Hongyan Yuan; Xin Li; Rik Derynck; Robert I Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

4.  Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.

Authors:  J J Lebrun; W W Vale
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

5.  Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase.

Authors:  Y Chen; A Bhushan; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Kinase-inactive splice variants of the activin type I receptor.

Authors:  K McKeehan; W I McKeehan; J Xu; L Liao
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-03       Impact factor: 2.416

7.  Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair.

Authors:  L I Gold; J J Sung; J W Siebert; M T Longaker
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

Review 8.  The Discovery and Early Days of TGF-β: A Historical Perspective.

Authors:  Harold L Moses; Anita B Roberts; Rik Derynck
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

9.  The transforming growth factor beta type II receptor can replace the activin type II receptor in inducing mesoderm.

Authors:  A Bhushan; H Y Lin; H F Lodish; C R Kintner
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.

Authors:  C S Craft; D Romero; C P H Vary; R C Bergan
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.